The Oncosearch | Oncotarget

Targeted drug combination therapy design based on driver genes Research Paper

Lilian Zsákai, Anna Sipos, Judit Dobos, Dániel Erős, Csaba Szántai-Kis, Péter Bánhegyi, János Pató, László Őrfi, Zsolt Matula, Gábor Mikala, György Kéri, István Peták, István Vályi-Nagy

Published Sep 3, 2019 · Vol. 10, No. 51 · pp. 5255-5266

Keywords: combination therapy, cancer driver gene, primary culture, small molecule compound, multiple myeloma

Regression of BRAF^V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

Peter Y.M. Woo, Tai-Chung Lam, Jenny K.S. Pu, Lai-Fung Li, Roland C.Y. Leung, Jason M.K. Ho, James T.F. Zhung, Belinda Wong, Timonthy S.K. Chan, Herbert H.F. Loong, Ho-Keung Ng

Published Jun 4, 2019 · Vol. 10, No. 38 · pp. 3818-3826

Keywords: glioblastoma, BRAF^V600E mutation, targeted therapies, BRAF-MEK inhibitors

A novel anti-melanoma SRC-family kinase inhibitor Research Paper

Ruth Halaban, Antonella Bacchiocchi, Robert Straub, Jian Cao, Mario Sznol, Deepak Narayan, Ahmed Allam, Michael Krauthammer, Tarek S. Mansour

Published Mar 19, 2019 · Vol. 10, No. 23 · pp. 2237-2251

Keywords: melanoma, SRC-family kinase inhibitors, MAPK, MITF

Sustained response of three pediatric BRAF^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Case Report

Stephanie A. Toll, Hung N. Tran, Jennifer Cotter, Alexander R. Judkins, Benita Tamrazi, Jaclyn A Biegel, Girish Dhall, Nathan J. Robison, Kaaren Waters, Palak Patel, Robert Cooper, Ashley S. Margol

Published Jan 11, 2019 · Vol. 10, No. 4 · pp. 551-557

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors Research Paper

Xuguang Zhu, Erik Holmsen, Sunmi Park, Mark C. Willingham, Jun Qi, Sheue-yann Cheng

Published Oct 23, 2018 · Vol. 9, No. 83 · pp. 35408-35421

Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling Research Paper

Katelyn N. Nelson, April N. Meyer, Clark G. Wang, Daniel J. Donoghue

Published Sep 28, 2018 · Vol. 9, No. 76 · pp. 34306-34319

CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma Research Paper

Michal Alon, Rand Arafeh, Joo Sang Lee, Sanna Madan, Shelly Kalaora, Adi Nagler, Tereza Abgarian, Polina Greenberg, Eytan Ruppin, Yardena Samuels

Published Jul 27, 2018 · Vol. 9, No. 58 · pp. 31264-31277

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells Research Paper

Eva Hajek, Franziska Krebs, Rebekka Bent, Katharina Haas, Antje Bast, Ivo Steinmetz, Andrea Tuettenberg, Stephan Grabbe, Matthias Bros

Published Jun 19, 2018 · Vol. 9, No. 47 · pp. 28294-28308

Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells Research Paper

Mahiro Iizuka-Ohashi, Motoki Watanabe, Mamiko Sukeno, Mie Morita, Ngoc Thi Hong Hoang, Takahiro Kuchimaru, Shinae Kizaka-Kondoh, Yoshihiro Sowa, Koichi Sakaguchi, Tetsuya Taguchi, Toshiyuki Sakai

Published Apr 13, 2018 · Vol. 9, No. 28 · pp. 19597-19612

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas Research Paper

Stefania Acciardo, Lionel Mignion, Nicolas Joudiou, Caroline Bouzin, Jean-FranÃ§ois Baurain, Bernard Gallez, BÃ©nÃ©dicte F. Jordan

Published Mar 30, 2018 · Vol. 9, No. 24 · pp. 16832-16846

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer Research Paper

Amir Noeparast, Philippe Giron, Sylvia De Brakeleer, Carolien Eggermont, Ulrike De Ridder, Erik Teugels, Jacques De GrÃ¨ve

Published Mar 23, 2018 · Vol. 9, No. 22 · pp. 16110-16123

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer Research Paper

Niranjan Awasthi, Sheena Monahan, Alexis Stefaniak, Margaret A. Schwarz, Roderich E. Schwarz

Published Dec 25, 2017 · Vol. 9, No. 4 · pp. 5274-5286

Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib Research Paper

Simona Caporali, Ester Alvino, Pedro Miguel Lacal, Federica Ruffini, Lauretta Levati, Laura Bonmassar, Alessandro Scoppola, Paolo Marchetti, Simona Mastroeni, Gian Carlo Antonini Cappellini, Stefania Dâ€™Atri

Published Dec 9, 2017 · Vol. 8, No. 69 · pp. 113472-113493

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways Priority Research Paper

Payal Jain, Amanda Silva, Harry J. Han, Shih-Shan Lang, Yuankun Zhu, Katie Boucher, Tiffany E. Smith, Aesha Vakil, Patrick Diviney, Namrata Choudhari, Pichai Raman, Christine M. Busch, Tim Delaney, Xiaodong Yang, Aleksandra K. Olow, Sabine Mueller, Daphne Haas-Kogan, Elizabeth Fox, Phillip B. Storm, Adam C. Resnick, Angela J. Waanders

Published Sep 15, 2017 · Vol. 8, No. 49 · pp. 84697-84713

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release Research Paper

Koung Jin Suh, Ji Hea Sung, Jin Won Kim, Song-Hee Han, Hye Seung Lee, Ahrum Min, Mi Hyun Kang, Ji Eun Kim, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Soo-Mee Bang, Seock-Ah Im, Jong Seok Lee

Published Jul 12, 2017 · Vol. 8, No. 38 · pp. 63901-63910

MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX) Research Paper

Kei Kawaguchi, Kentaro Igarashi, Takashi Murakami, Tasuku Kiyuna, Thinzar M. Lwin, Ho Kyoung Hwang, Jonathan C. Delong, Bryan M. Clary, Michael Bouvet, Michiaki Unno, Robert M. Hoffman

Published May 7, 2017 · Vol. 8, No. 29 · pp. 47490-47496

Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing Research Paper

Mengdan Li, Lihong Chen, Yiping Qu, Fang Sui, Qi Yang, Meiju Ji, Bingyin Shi, Mingwei Chen, Peng Hou

Published Mar 31, 2017 · Vol. 8, No. 22 · pp. 36319-36330

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase Research Paper

Corinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, Heike Niessner, Anja Schmitt, Elena Makino, Andrea Forschner, Stephan Hailfinger, Claus Garbe, Birgit Schittek

Published Mar 15, 2017 · Vol. 8, No. 22 · pp. 35761-35775

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS^Q61K melanoma Priority Research Paper

Cynthia M. Simbulan-Rosenthal, Sivanesan Dakshanamurthy, Anirudh Gaur, You-Shin Chen, Hong-Bin Fang, Maryam Abdussamad, Hengbo Zhou, John Zapas, Valerie Calvert, Emanuel F. Petricoin, Michael B. Atkins, Stephen W. Byers, Dean S. Rosenthal

Published Feb 2, 2017 · Vol. 8, No. 8 · pp. 12576-12595

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo Research Paper

Laurence Booth, Jane L. Roberts, Cindy Sander, John Lee, John M. Kirkwood, Andrew Poklepovic, Paul Dent

Published Jan 27, 2017 · Vol. 8, No. 10 · pp. 16367-16386

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Targeted drug combination therapy design based on driver genes Research Paper

Regression of BRAF^V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

A novel anti-melanoma SRC-family kinase inhibitor Research Paper

Sustained response of three pediatric BRAF^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Case Report

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors Research Paper

Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling Research Paper

CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma Research Paper

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells Research Paper

Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells Research Paper

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas Research Paper

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer Research Paper

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer Research Paper

Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib Research Paper

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways Priority Research Paper

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release Research Paper

MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX) Research Paper

Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing Research Paper

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase Research Paper

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS^Q61K melanoma Priority Research Paper

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Targeted drug combination therapy design based on driver genes Research Paper

Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

A novel anti-melanoma SRC-family kinase inhibitor Research Paper

Sustained response of three pediatric BRAFV600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Case Report

Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors Research Paper

Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling Research Paper

CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma Research Paper

BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells Research Paper

Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells Research Paper

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas Research Paper

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer Research Paper

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer Research Paper

Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib Research Paper

Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways Priority Research Paper

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release Research Paper

MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX) Research Paper

Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing Research Paper

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase Research Paper

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma Priority Research Paper

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo Research Paper

Regression of BRAF^V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases Case Report

Sustained response of three pediatric BRAF^V600E mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy Case Report

The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS^Q61K melanoma Priority Research Paper